PODD - インスレット (Insulet Corporation)

PODDのニュース

   $1000 Invested In Insulet 5 Years Ago Would Be Worth This Much Today  2022/08/23 14:41:04 Benzinga
Insulet (NASDAQ: PODD ) has outperformed the market over the past 5 years by 24.25% on an annualized basis producing an average annual return of 35.42%. Currently, Insulet has a market capitalization of $18.24 billion. Buying $1000 In PODD: If an … Full story available on Benzinga.com
   Cowen Reiterates Outperform on Insulet on Omnipod 5 Label Expansion  2022/08/22 18:00:02 Investing.com
https://www.investing.com/news/pro/cowen-reiterates-outperform-on-insulet-on-omnipod-5-label-expansion-432SI-2877639
   Insulet''s Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes  2022/08/22 13:59:57 FierceBiotech
Insulet''s Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes apark Mon, 08/22/2022 - 09:59
   PODD stock on watch on FDA nod for Omnipod 5 in young children (NASDAQ:PODD)  2022/08/22 10:35:26 Seeking Alpha
Insulin pump maker Insulet Corporation (PODD) announced Monday that the FDA had greenlighted the company’s Omnipod 5 Automated Insulin Delivery System for use in children aged 2 – 5…
   Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes  2022/08/22 10:00:00 Investor Insulet
Omnipod 5 is the first tubeless AID System cleared in the U.S. for preschool children ACTON, Mass. --(BUSINESS WIRE)--Aug. 22, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today
   Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2022 Results - Earnings Call Transcript  2022/05/06 21:23:07 Seeking Alpha
Insulet Corporation (NASDAQ:NASDAQ:PODD) Q1 2022 Earnings Conference Call May 05, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Shacey Petrovic -…
   Insulet -11% after Wells Fargo lowers PT after Q1 earnings  2022/05/06 17:56:21 Seeking Alpha
Insulet (PODD) falls 11% after Wells Fargo analyst cuts PT to $345 from $357.The company''s Q1 earnings topped expectations and announced CEO transition.
   Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is ''Progressing Very Well''  2022/05/06 13:55:52 Benzinga
Insulet Corporation (NASDAQ: PODD ) posted Q1 profits of $27.8 million , or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off to a great start … Full story available on Benzinga.com
   May 5, 2022 4:30 PM EDT : Q1 2022 Insulet Corporation Earnings Conference Call  2022/05/05 20:30:00 Investor Insulet
The Investor Relations website contains information about Insulet Corporation''s business for stockholders, potential investors, and financial analysts.
   Insulet CEO Shacey Petrovic to step down  2022/05/05 20:26:30 Seeking Alpha
Insulet (PODD) said Thursday Shacey Petrovic will step down from her role as president and CEO for personal reasons, effective Jun. 1.Petrovic will continue to serve on PODD''s board
   Insulet Corporation (PODD) Could Be Possessing A Gold Mine  2022/02/26 12:30:00 Stocks Register
Insulet Corporation (NASDAQ:PODD) concluded the trading at $262.37 on Friday, February 25 with a rise of 2.74% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $255.37 and 5Y monthly beta was reading 0.70 with its price kept floating in the range … Insulet Corporation (PODD) Could Be Possessing A Gold Mine Read More »
   Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%  2022/02/24 11:41:07 Benzinga
Insulet Corp''s (NASDAQ: PODD ) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million , exceeding the consensus of $301.06 million. The company brought in $275.8 million in revenues for its Omnipod insulin delivery platform for the quarter, representing a 19.3% increase. Insulet posted Q4 EPS of $0.42, a shift from EPS loss of $(0.26) a year … Full story available on Benzinga.com
   Insulet Corporation (PODD) CEO Shacey Petrovic On Q4 2021 Results - Earnings Call Transcript  2022/02/24 01:45:25 Seeking Alpha
   Insulet GAAP EPS of $0.42 beats by $0.11, revenue of $307.7M beats by $7.13M (NASDAQ:PODD)  2022/02/23 21:04:13 Seeking Alpha
Insulet press release (PODD): Q4 GAAP EPS of $0.42 beats by $0.11.Revenue of $307.7M (+25.0% Y/Y) beats by $7.13M.Gross margin of 69.3%, up 380 basis points.Adjusted EBITDA of…
   Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year  2022/02/23 21:01:00 Business Wire
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2021. Full Year Financial Highlights: Full Year 2021 revenue of $1.1 billion, up 21.5%, or 19.7% in constant currency1, compared to $904.4 million in the prior year, at the high-end of the guidance range of 18% to 20% in constan

calendar